Tumor Proliferation Markers
Tumor Proliferation Markers - Related Videos
03:19
Transduction to Label PDX Tumor Cells: Introducing Lentivirus Expressing Fluorescent Marker into the Tumor Cell In Vitro
0 Views •
2023
The following video describes a technique of transduction to label (patient-derived xenografts) PDX tumor cells, which is used for introducing lentivirus expressing green-fluorescent protein and luciferase reporters into the tumor cell in vitro.
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
0 Views •
Cited by 23 •
2014
An example of a nano drug based on polymalic acid is presented towards the rational design of personalized medicine that is applicable to cancer. It describes the synthesis of a nano drug to treat Her2-positive human breast cancer in a nude mouse.
02:23
Abnormal Proliferation
0 Views •
2021
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:23
Abnormal Proliferation
0 Views •
2023
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:46
An In Vitro Assay for Evaluating the Immunomodulatory Impact of Monocytes on Leukocyte Proliferation
0 Views •
2025
This video demonstrates an in vitro assay to explore the immunomodulatory influence of mesenchymal stem cells (MSCs) on effector T cell proliferation. The assay includes co-culturing MSCs with PBMCs to induce the monocyte population to acquire an immunomodulatory phenotype, leading to the secretion of interleukin-10 (IL-10). Following incubation with activated CD4+ T cells, the induced monocytes effectively suppress T cell proliferation.
FAQs
Markers linked to cell-cycle activity help estimate the fraction of tumor cells engaged in division at the time examined. A higher measured proliferative fraction indicates greater activity in that sample, but it is not a complete measure of tumor aggressiveness. Researchers therefore interpret the result with tumor type, grade, genetic features, and other clinical findings.
Ki-67 is useful because it exemplifies a molecule associated with active cell cycling that can be visualized in tumor tissue. Immunohistochemical staining makes the relevant cells detectable and supports estimation of the proportion showing the marker. This provides a measurable readout for comparing tumor biology, while the marker level still requires disease-specific interpretation.
The measured fraction captures proliferative activity, not every determinant of tumor behavior. Tumor type, grade, genetic features, and other clinical findings can change how a given level should be understood. Consequently, similar marker results may support different biological or prognostic interpretations in different cancers, so the value lies in integrated assessment rather than isolated measurement.
Serial measurements can show whether proliferative activity changes after an experimental treatment or during follow-up. A decrease may provide evidence that the treatment is associated with reduced cell-cycle activity in the examined tumor, whereas comparison across time requires consistent interpretation. In cancer research, this approach helps connect treatment exposure with biological response.
An investigator examines tumor tissue with immunohistochemical staining directed at a cell-cycle-associated molecule such as Ki-67, then determines the proportion of tumor cells showing the relevant signal. That proportion becomes the experimental readout for proliferative activity. The result can then be compared between samples, treatment groups, or time points.
Researchers use these markers to characterize tumor biology, compare experimental treatments, and support prognostic assessment. In a study, the measurement can provide a common biological outcome for examining whether tumors differ in proliferative activity or whether that activity changes with therapy. It is most informative when reported alongside tumor type, grade, genetic features, and other findings.